8-K: Keros Therapeutics Announces Positive Phase 2 Clinical Trial Data for Elritercept in MDS and Myelofibrosis

Keros Therapeutics presented promising data from its Phase 2 trials of elritercept, showing durable transfusion independence in MDS patients and improvements in hematopoiesis and symptoms in myelofibrosis patients.

Summary

• Keros Therapeutics presented additional data from two ongoing Phase 2 clinical trials of elritercept (KER-050) at the 66th American Society of Hematology Annual Meeting and Exposition.
• One trial focused on patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS), and the other on patients with myelofibrosis (MF).
• In the MDS trial, 55.2% of patients achieved an overall erythroid response over the first 24 weeks of treatment, with a median duration of transfusion independence of 134.1 weeks.
• 39.1% of transfusion-independent evaluable patients achieved transfusion independence for at least eight weeks over the first 24 weeks of treatment.
• In a subgroup of non-transfused MDS patients, 93.3% had an increase in hemoglobin greater than 1.0 g/dL and 86.7% had a hematological improvement-erythroid response.
• In the myelofibrosis trial, 82.8% of non-transfusion dependent patients showed increases in hemoglobin over a 12-week period.
• 63.4% of patients who received at least three red blood cell units per 12 weeks at baseline showed reductions in transfusion burden over 12 weeks.
• 24.4% of patients with reductions in transfusion burdens achieved transfusion independence.
• 40% of patients with baseline spleen size greater than 450 cm3 showed a reduction in spleen volume at week 24.
• 66.7% of patients with significant disease symptoms showed a reduction in symptoms at week 24.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial data for elritercept, indicating a strong potential for the drug. The sentiment is high due to the promising efficacy and tolerability results, although there are some risks associated with the company's financial position and development process.

Positives

• Elritercept showed durable transfusion independence in lower-risk MDS patients, including those with high transfusion burden.
• The treatment led to improvements in patient-reported measures of fatigue in MDS patients.
• Elritercept demonstrated the potential to ameliorate ineffective hematopoiesis and address cytopenias in myelofibrosis patients.
• The drug showed reductions in spleen volume and improved total symptom scores in myelofibrosis patients.
• The data supports the rationale for the planned Phase 3 RENEW registrational trial of elritercept in transfusion-dependent patients with very low-, low-, and intermediate risk MDS.
• Elritercept was generally well-tolerated in both trials.

Negatives

• There were four fatal treatment-emergent adverse events in the MDS trial, though deemed unrelated to treatment.
• There were six fatal treatment-emergent adverse events in the myelofibrosis trial, also deemed unrelated to treatment.
• The most commonly reported treatment-emergent adverse events in the MDS trial were diarrhea, fatigue, COVID-19, dyspnea, dizziness, anemia, nausea and epistaxis.
• The most commonly reported treatment-emergent adverse events in the myelofibrosis trial were thrombocytopenia and diarrhea.
• Some patients experienced Grade 3 or higher treatment-related thrombocytopenia in the myelofibrosis trial.

Risks

• The company has a limited operating history and has experienced historical losses.
• The company's ability to raise additional funding to complete the development and commercialization of its product candidates is a risk.
• The company is dependent on the success of its product candidates, including elritercept.
• There is a risk of delays in initiating, enrolling, or completing clinical trials.
• Initial or interim results from clinical trials may not be predictive of final results.
• The company faces competition from third parties developing products for similar uses.
• The company's ability to obtain, maintain, and protect its intellectual property is a risk.
• The company is dependent on third parties for manufacturing, clinical trials, and preclinical studies.

Future Outlook

Keros plans to commence enrollment of its Phase 3 RENEW clinical trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low-, or intermediate-risk MDS soon.

Management Comments

• The data we presented at ASH supports the differentiated profile of elritercept in both MDS and MF, said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer.
• We look forward to commencing enrollment of our Phase 3 RENEW clinical trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low-, or intermediate-risk MDS soon, so that we can take the next step towards bringing this potential treatment option to patients.

Industry Context

The announcement is significant as it provides further evidence of the potential of elritercept in treating hematological disorders, specifically MDS and myelofibrosis, which are areas of unmet medical need. The positive data could position Keros as a key player in the development of novel therapies for these conditions.

Comparison to Industry Standards

• The reported median duration of transfusion independence of 134.1 weeks in MDS patients is a strong result, comparing favorably to existing treatments and other investigational therapies in this space.
• The erythroid response rate of 55.2% in MDS patients is also competitive, suggesting a meaningful clinical benefit.
• The improvements in hemoglobin levels and reductions in transfusion burden in myelofibrosis patients are encouraging, particularly in the context of ruxolitinib-associated anemia, a common challenge in this patient population.
• The observed reductions in spleen volume and symptom scores in myelofibrosis patients are also clinically relevant and compare favorably to other treatments.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial data, potentially increasing the company's stock value.
• Patients with MDS and myelofibrosis may benefit from the development of elritercept as a new treatment option.
• Employees of Keros may be motivated by the positive results and the potential for the company's growth.
• The positive results may attract potential partners and investors.

Next Steps

• Keros plans to commence enrollment of its Phase 3 RENEW clinical trial for elritercept in transfusion-dependent MDS patients.
• The company will continue to monitor and analyze data from the ongoing Phase 2 trials.

Key Dates

Keywords

elritercept, myelodysplastic syndromes, myelofibrosis, anemia, transfusion independence, hematopoiesis, clinical trial, cytopenias, hematology, TGF-beta